Venatorx Pharmaceuticals’ cefepime-taniborbactam was superior to standard of care meropenem for treating complicated urinary tract infections in Phase 3 trials, the Pennsylvania-based company announced last week.
The investigational antibiotic—which targets carbapenem-resistant Enterobacterales and P. aeruginosa—generated bacterial eradication in 70% of participants compared to 58% treated with meropene, and cefepime-taniborbactam’s superiority was maintained through a late follow-up,…
Seres Therapeutics’ oral microbiome treatment for C. difficile infections (CDI) proved superior to placebo in reducing CDI recurrence, according to Phase 3 data published last week in the New England Journal of Medicine. Touting the “first-ever positive pivotal clinical results for a targeted microbiome drug,” the Massachusetts-based company said in a press release it would finalize its U.S. FDA Biologics License Application for SER-109 in mid-2022.
The treatment boasts FDA…
A therapy for the prevention of recurrent C. difficile infection (CDI) in high-risk patients has met the primary endpoint in a Phase 2 trial, Vedanta Biosciences announced Tuesday. The Massachusetts-based company’s VE303, an orally administered live biotherapeutic, yielded a 31.7% absolute risk reduction in rate of recurrence versus placebo, according to a press release.
Based on the Phase 2 data, the U.S. Biomedical Advanced Research and Development Authority (BARDA) exercised an…
CARB-X announced Tuesday an award of up to $12.5 million to North Carolina-based Locus Biosciences to develop LBP-KP01, a CRISPR-Cas3-enhanced bacteriophage cocktail that targets recurrent urinary tract infections (UTIs) caused by K. pneumoniae.
Locus is also developing a CRISPR-engineered bacteriophage cocktail against recurrent UTIs caused by E. coli—a project that secured up to $77 million in September from the U.S. Biomedical Advanced Research and Development Authority.
The U.S. Biomedical Advanced Research and Development Authority (BARDA) announced two awards Wednesday for “advanced development” of investigational drugs targeting antibiotic-resistant infections.
Massachusetts-based Vedanta Biosciences scored up to $76.9 million ($7.4 million upfront) to complete an ongoing Phase 2 trial and continue clinical development of VE303—a novel, human microbiome-derived treatment for high-risk C. difficile infection. The drug becomes the second CARB-X-…
CARB-X on Tuesday announced its first investment with a major multinational pharma company, awarding up to $7.5 million to GSK to develop a treatment for recurrent urinary tract infections caused by E. coli.
The funds will support a Phase 1 study—initiated this month—of GSK3882347 and also pay for scale-up of the oral small molecule drug, according to a CARB-X press release.